French Drugmakers Face 2.5 BFr Payment Crunch

15 January 1996

Analysis of the controversial health care reform plan of French Prime Minister Alain Juppe (Marketletters passim) has underlined divergent interests in the pharmaceutical industry because the financial levy on some companies will be far greater than on others.

One French drug sector source said last week that "the plan will be a bitter pill for everybody - but for some companies it will be impossible to swallow."

The industry remains divided over how the levy will be shared. The drug wholesaler companies already pay a provisional levy, which was introduced in 1991, and will pay an estimated 900 million French francs ($183.5 million) this year, bringing the total levy on the French drug sector to almost 3.5 billion francs ($713.7 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight